FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952108487> ?p ?o ?g. }

• W2952108487 endingPage "1141" @default.
• W2952108487 startingPage "1141" @default.
• W2952108487 abstract "Patients with recurrent ovarian carcinoma frequently develop resistance to platinum-based chemotherapy, at which time treatment options become limited.To evaluate the poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor niraparib combined with pembrolizumab in patients with recurrent ovarian carcinoma.The TOPACIO/KEYNOTE-162 (Niraparib in Combination With Pembrolizumab in Patients With Triple-Negative Breast Cancer or Ovarian Cancer) trial, an open-label, single-arm phases 1 and 2 study enrolled women with advanced or metastatic triple-negative breast cancer (TNBC) or recurrent ovarian carcinoma, irrespective of BRCA mutation status. Median follow-up was 12.4 months (range, 1.2 to ≥23.0 months). Data were collected from April 15, 2016, through September 4, 2018, with September 4, 2018, as a data cutoff, and analyzed from September 4, 2018, through January 30, 2019.The recommended phase 2 dose (RP2D) was 200 mg of oral niraparib once daily and 200 mg of intravenous pembrolizumab on day 1 of each 21-day cycle.The primary objectives of phase 1 were to evaluate dose-limiting toxic effects and establish the RP2D and dosing schedule. The primary objective of phase 2 was to assess objective response rate (ORR; complete plus partial responses). Results from the phase 1 ovarian carcinoma and TNBC cohorts and phase 2 ovarian carcinoma cohort are reported. Because of the similarity in the phase 1 and 2 ovarian carcinoma populations, the data were pooled to perform an integrated efficacy analysis.Fourteen patients (9 with ovarian carcinoma and 5 with TNBC) in phase 1 and 53 patients with ovarian carcinoma in phase 2 were enrolled, for a pooled ovarian carcinoma cohort of 62 patients (median age, 60 years [range, 46-83 years]). In the integrated efficacy phases 1 and 2 ovarian carcinoma population (60 of 62 evaluable patients), ORR was 18% (90% CI, 11%-29%), with a disease control rate of 65% (90% CI, 54%-75%), including 3 (5%) with confirmed complete responses, 8 (13%) with confirmed partial responses, 28 (47%) with stable disease, and 20 (33%) with progressive disease. The ORRs were consistent across subgroups based on platinum-based chemotherapy sensitivity, previous bevacizumab treatment, or tumor BRCA or homologous recombination deficiency (HRD) biomarker status. Median duration of response was not reached (range, 4.2 to ≥14.5 months). At data cutoff, 2 patients with a response and 1 patient with stable disease continued to receive treatment.Niraparib in combination with pembrolizumab is tolerable, with promising antitumor activity for patients with ovarian carcinoma who have limited treatment options regardless of platinum status, biomarker status, or prior treatment with bevacizumab. Responses in patients without tumor BRCA mutations or non-HRD cancers were higher than expected with either agent as monotherapy.ClinicalTrials.gov identifier: NCT02657889." @default.
• W2952108487 created "2019-06-27" @default.
• W2952108487 creator A5005266772 @default.
• W2952108487 creator A5019377044 @default.
• W2952108487 creator A5023923887 @default.
• W2952108487 creator A5028833538 @default.
• W2952108487 creator A5032881252 @default.
• W2952108487 creator A5037677450 @default.
• W2952108487 creator A5039952665 @default.
• W2952108487 creator A5044100563 @default.
• W2952108487 creator A5044648110 @default.
• W2952108487 creator A5045166306 @default.
• W2952108487 creator A5048222855 @default.
• W2952108487 creator A5055462512 @default.
• W2952108487 creator A5057155689 @default.
• W2952108487 creator A5058249824 @default.
• W2952108487 creator A5060086956 @default.
• W2952108487 creator A5063136834 @default.
• W2952108487 creator A5069337573 @default.
• W2952108487 creator A5073189857 @default.
• W2952108487 creator A5076246054 @default.
• W2952108487 creator A5077967611 @default.
• W2952108487 creator A5083373965 @default.
• W2952108487 creator A5084420374 @default.
• W2952108487 creator A5086089361 @default.
• W2952108487 creator A5089462873 @default.
• W2952108487 creator A5089955620 @default.
• W2952108487 date "2019-08-01" @default.
• W2952108487 modified "2023-10-14" @default.
• W2952108487 title "Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma" @default.
• W2952108487 cites W1999659306 @default.
• W2952108487 cites W2019607817 @default.
• W2952108487 cites W2043178214 @default.
• W2952108487 cites W2054165449 @default.
• W2952108487 cites W2054388008 @default.
• W2952108487 cites W2094666871 @default.
• W2952108487 cites W2117964602 @default.
• W2952108487 cites W2128746885 @default.
• W2952108487 cites W2170928115 @default.
• W2952108487 cites W2171972386 @default.
• W2952108487 cites W2177405394 @default.
• W2952108487 cites W2199466904 @default.
• W2952108487 cites W2509217584 @default.
• W2952108487 cites W2528228811 @default.
• W2952108487 cites W2587333476 @default.
• W2952108487 cites W2595030994 @default.
• W2952108487 cites W2751912349 @default.
• W2952108487 cites W2766806972 @default.
• W2952108487 cites W2768434280 @default.
• W2952108487 cites W2802480234 @default.
• W2952108487 cites W2804717005 @default.
• W2952108487 cites W2890261294 @default.
• W2952108487 cites W2914850591 @default.
• W2952108487 doi "https://doi.org/10.1001/jamaoncol.2019.1048" @default.
• W2952108487 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6567832" @default.
• W2952108487 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31194228" @default.
• W2952108487 hasPublicationYear "2019" @default.
• W2952108487 type Work @default.
• W2952108487 sameAs 2952108487 @default.
• W2952108487 citedByCount "317" @default.
• W2952108487 countsByYear W29521084872019 @default.
• W2952108487 countsByYear W29521084872020 @default.
• W2952108487 countsByYear W29521084872021 @default.
• W2952108487 countsByYear W29521084872022 @default.
• W2952108487 countsByYear W29521084872023 @default.
• W2952108487 crossrefType "journal-article" @default.
• W2952108487 hasAuthorship W2952108487A5005266772 @default.
• W2952108487 hasAuthorship W2952108487A5019377044 @default.
• W2952108487 hasAuthorship W2952108487A5023923887 @default.
• W2952108487 hasAuthorship W2952108487A5028833538 @default.
• W2952108487 hasAuthorship W2952108487A5032881252 @default.
• W2952108487 hasAuthorship W2952108487A5037677450 @default.
• W2952108487 hasAuthorship W2952108487A5039952665 @default.
• W2952108487 hasAuthorship W2952108487A5044100563 @default.
• W2952108487 hasAuthorship W2952108487A5044648110 @default.
• W2952108487 hasAuthorship W2952108487A5045166306 @default.
• W2952108487 hasAuthorship W2952108487A5048222855 @default.
• W2952108487 hasAuthorship W2952108487A5055462512 @default.
• W2952108487 hasAuthorship W2952108487A5057155689 @default.
• W2952108487 hasAuthorship W2952108487A5058249824 @default.
• W2952108487 hasAuthorship W2952108487A5060086956 @default.
• W2952108487 hasAuthorship W2952108487A5063136834 @default.
• W2952108487 hasAuthorship W2952108487A5069337573 @default.
• W2952108487 hasAuthorship W2952108487A5073189857 @default.
• W2952108487 hasAuthorship W2952108487A5076246054 @default.
• W2952108487 hasAuthorship W2952108487A5077967611 @default.
• W2952108487 hasAuthorship W2952108487A5083373965 @default.
• W2952108487 hasAuthorship W2952108487A5084420374 @default.
• W2952108487 hasAuthorship W2952108487A5086089361 @default.
• W2952108487 hasAuthorship W2952108487A5089462873 @default.
• W2952108487 hasAuthorship W2952108487A5089955620 @default.
• W2952108487 hasBestOaLocation W29521084871 @default.
• W2952108487 hasConcept C121608353 @default.
• W2952108487 hasConcept C126322002 @default.
• W2952108487 hasConcept C143998085 @default.
• W2952108487 hasConcept C2777546739 @default.
• W2952108487 hasConcept C2777701055 @default.
• W2952108487 hasConcept C2780057760 @default.

• next